Organization
Hospital Universitario, 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
2 abstracts
Abstract
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).Org: The Ohio State University Comprehensive Cancer Center, Columbus, OH, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, SF Nectarie Oncology Center, Craiova, Romania, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, L’institut du Thorax, Nantes, France,
Abstract
Comparison between liquid biopsy and tissue NGS in two cohorts of advanced NSCLC.Org: Department of Medical Oncology, Hospital Universitario 12 de Octubre. Universidad Complutense de Madrid, Madrid, Spain, Sapienza University of Rome, Medical Oncology Department, Policlinico Umberto I, Roma, Italy, Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain, Pathology Department, Hospital Universitario 12 de Octubre. Universidad Complutense de Madrid. Research Institute Hospital 12 de Octubre (i+12). CIBERONC, Madrid, Spain,